Concert Pharmaceuticals Inc. (CNCE) 13.36 $CNCE
Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration
Business Wire - Wed Sep 17, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized, double-blind, single ascending dose Phase 1 clinical trial designed to assess the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects. The Phase 1 clinical program will also evaluate multiple ascending doses of CTP-730 and is expected to be completed in 2015.
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
Concert Pharmaceuticals triggers USD2m milestone payment for the clinical progress of AVP-786 for major depressive disorder
M2 - Wed Aug 27, 5:57AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) said on Tuesday that it will receive a USD2m milestone payment for the clinical progress of AVP-786 for the adjunctive treatment of major depressive disorder under its development and license agreement with Avanir Pharmaceuticals.
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
Business Wire - Tue Aug 26, 8:01AM CDT
Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder.
Concert Pharmaceuticals to Present at Robert W. Baird 2014 Healthcare Conference on September 4, 2014
Business Wire - Thu Aug 21, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present an overview at the Robert W. Baird & Co. 2014 Healthcare Conference, September 4, 2014 at 10:15 a.m. EDT at The New York Palace Hotel in New York City.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Aug 13, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update
Business Wire - Tue Aug 12, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2014.
Concert Pharmaceuticals to Report Second Quarter 2014 Results on August 12, 2014
Business Wire - Tue Aug 05, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2014 financial results on Tuesday, August 12, 2014 before the financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss second quarter financial results and provide a business and clinical pipeline update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
Fibromyalgia - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:25PM CDT
Jazz Pharmaceuticals (JAZZ) and Concert Pharmaceuticals (CNCE) announced the initiation of a phase I study on JZP-386.
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
Business Wire - Mon Jul 21, 3:05PM CDT
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate--the active ingredient in Xyrem(R) (sodium oxybate) oral solution.
Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
Business Wire - Wed Jul 16, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the FDA has provided notification that the Company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the Company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial.
Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 10:40AM CDT
Concert Pharma's meeting with the FDA ended on a positive note with the latter agreeing to the company's phase III development plan on CTP-499.
Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499
Business Wire - Tue Jul 08, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for CTP-499, its investigational therapy targeting diabetic nephropathy.
Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures
Narcolepsy - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vtg2g/narcolepsy) has announced the addition of the "Narcolepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - BIOPROJET - Concert Pharmaceuticals. - Evotec - Grupo Ferrer Internacional - Jazz Pharmaceuticals - SK Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/3vtg2g/narcolepsy
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration
Business Wire - Wed Sep 17, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation. Concert will conduct the randomized, double-blind, single ascending dose Phase 1 clinical trial designed to assess the safety, tolerability and pharmacokinetics of CTP-730. The study is expected to enroll up to 40 healthy subjects. The Phase 1 clinical program will also evaluate multiple ascending doses of CTP-730 and is expected to be completed in 2015.
Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 7:57AM CDT
Concert Pharmaceuticals, Inc. (CNCE) was a big mover last session, as the company saw its shares rise nearly 26% on the day.
4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
Concert Pharmaceuticals triggers USD2m milestone payment for the clinical progress of AVP-786 for major depressive disorder
M2 - Wed Aug 27, 5:57AM CDT
Biopharmaceutical company Concert Pharmaceuticals (NasdaqGM:CNCE) said on Tuesday that it will receive a USD2m milestone payment for the clinical progress of AVP-786 for the adjunctive treatment of major depressive disorder under its development and license agreement with Avanir Pharmaceuticals.
Concert Pharmaceuticals Achieves $2 Million Milestone for AVP-786 Under Avanir Pharmaceuticals Collaboration
Business Wire - Tue Aug 26, 8:01AM CDT
Concert Pharmaceuticals, Inc. (NASDQ: CNCE) today announced that it has achieved a $2 million milestone under its development and license agreement with Avanir Pharmaceuticals, Inc. for the clinical progression of AVP-786. The milestone is a result of Avanir initiating dosing in a Phase 2 clinical trial with AVP-786 for the adjunctive treatment of major depressive disorder.
Concert Pharmaceuticals to Present at Robert W. Baird 2014 Healthcare Conference on September 4, 2014
Business Wire - Thu Aug 21, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present an overview at the Robert W. Baird & Co. 2014 Healthcare Conference, September 4, 2014 at 10:15 a.m. EDT at The New York Palace Hotel in New York City.
4 Stocks Under $10 Making Big Moves
at The Street - Wed Aug 13, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Concert Pharmaceuticals Reports Second Quarter 2014 Financial Results and Provides Company Update
Business Wire - Tue Aug 12, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the second quarter of 2014.
Concert Pharmaceuticals to Report Second Quarter 2014 Results on August 12, 2014
Business Wire - Tue Aug 05, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its second quarter 2014 financial results on Tuesday, August 12, 2014 before the financial markets open. The Company will host a conference call and webcast at 8:30 a.m. EDT to discuss second quarter financial results and provide a business and clinical pipeline update. Individuals interested in participating in the call should dial (855) 354-1855 (U.S. and Canada) or (484) 365-2865 (International).
Fibromyalgia - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Jazz Pharmaceuticals/Concert Pharmaceuticals Start Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 22, 4:25PM CDT
Jazz Pharmaceuticals (JAZZ) and Concert Pharmaceuticals (CNCE) announced the initiation of a phase I study on JZP-386.
Jazz Pharmaceuticals and Concert Pharmaceuticals Provide a Phase 1 Clinical Trial Update on JZP-386
Business Wire - Mon Jul 21, 3:05PM CDT
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of the first Phase 1 clinical trial of JZP-386, a deuterium-containing analog of sodium oxybate--the active ingredient in Xyrem(R) (sodium oxybate) oral solution.
Concert Pharmaceuticals Announces FDA Lifts Partial Clinical Hold for CTP-354, A Novel Drug Candidate for Spasticity
Business Wire - Wed Jul 16, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that the FDA has provided notification that the Company has completed the necessary preclinical toxicology testing in order to administer repeated doses of CTP-354 in excess of 6 mg per day, lifting its partial clinical hold. As a result, the Company intends to initiate dosing of 12 mg per day of CTP-354 in the third quarter of this year as part of its ongoing multiple ascending dose Phase 1 trial.
Concert Pharmaceuticals' Shares Slip Despite Favorable FDA Meeting - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 10:40AM CDT
Concert Pharma's meeting with the FDA ended on a positive note with the latter agreeing to the company's phase III development plan on CTP-499.
Concert Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA for CTP-499
Business Wire - Tue Jul 08, 6:00AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for CTP-499, its investigational therapy targeting diabetic nephropathy.
Global Seizures Therapeutics Pipeline Review, H1 2014 - 9 Companies & 12 Drug Profiles
M2 - Tue Jul 01, 9:43AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ccl3gq/seizures) has announced the addition of the "Seizures - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Alexza Pharmaceuticals, Inc. - Novartis AG - Acorda Therapeutics, Inc. - Pfizer Inc. - Upsher-Smith Laboratories, Inc. - Concert Pharmaceuticals, Inc. - Advicenne Pharma - Ultragenyx Pharmaceutical Inc. - Sage Therapeutics Drug Profiles - diazepam - midazolam hydrochloride - everolimus - diazepam - UX-007 - topiramate - alprazolam - ADV-6208 - C-10068 - CCG-63802 - Dihydroxyflavone - SAGE-NCE For more information visit http://www.researchandmarkets.com/research/ccl3gq/seizures
Narcolepsy - Pipeline Review, H1 2014
M2 - Thu Jun 26, 4:06AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3vtg2g/narcolepsy) has announced the addition of the "Narcolepsy - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Narcolepsy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Narcolepsy and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Scope - The report provides a snapshot of the global therapeutic landscape of Narcolepsy - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Narcolepsy and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Narcolepsy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Narcolepsy pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Mentioned: - BIOPROJET - Concert Pharmaceuticals. - Evotec - Grupo Ferrer Internacional - Jazz Pharmaceuticals - SK Biopharmaceuticals For more information visit http://www.researchandmarkets.com/research/3vtg2g/narcolepsy
Hercules Technology Growth Capital Announces Portfolio Update for Q1 2014; Quarter Marked By Continued Portfolio Diversity and Growth and Significant Number of Liquidity Events
Business Wire - Wed Apr 02, 7:02AM CDT
--5 Completed IPO Liquidity Events Q1 2014
Concert Pharmaceuticals (CNCE) Catches Eye: Stock Up 9.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 8:25AM CDT
Concert Pharmaceuticals was a big mover last session, with shares rising over 9% on the day.
Concert Pharmaceuticals Announces Filing of its Annual Report on Form 10-K
Business Wire - Mon Mar 31, 6:15AM CDT
Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) announced today that it has filed its Annual Report on Form 10-K for the year ended December 31, 2013 with the Securities and Exchange Commission.
